335078-23-4Relevant articles and documents
A novel series of potent and selective PDE5 inhibitors with potential for high and dose-independent oral bioavailability
Allerton, Charlotte M. N.,Barber, Christopher G.,Beaumont, Kevin C.,Brown, David G.,Cole, Susan M.,Ellis, David,Lane, Charlotte A. L.,Maw, Graham N.,Mount, Natalie M.,Rawson, David J.,Robinson, Colin M.,Street, Stephen D. A.,Summerhill, Nicholas W.
, p. 3581 - 3594 (2007/10/03)
Sildenafil (5-[2-ethoxy-5-(4-methyl-1-piperazinylsulfonyl)phenyl]-1-methyl- 3-n-propyl-1,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one), a potent and selective phosphodiesterase type 5 (PDE5) inhibitor, provided the first oral treatment for male erectile dy
Process for the preparation of pyrazolo[4,3-d]pyrimidin-7-ones and intermediates thereof
-
Page 18-19, (2010/01/31)
A process is provided for the preparation of compounds of formula (I) herein comprising reacting a compound of formula (II), (III), (IV) or (V) in the presence of-OR3 and a hydroxide trapping agent or in the case of compounds of formula (IV) reacting in the presence of an auxiliary base and a hydroxide trapping agent (i.e.-OR3 is substituted by the auxiliary base), wherein X is a leaving group and R1 to R4 are as defined.
Pyrazolopyrimidine derivatives
-
Page 75, (2010/01/31)
The present invention provides a compound of formula (I): where Q is a group of formula: These compounds inhibit cyclic guanosine 3',5'-monophosphate phosphodiesterases (cGMP PDEs). More notably, the compounds are potent and selective inhibitors of the type 5 cyclic guanosine 3',5'-monophosphate phosphodiesterases and have utility therefore in a variety of therapeutic areas. In particular, the present compounds are of value for the curative or prophylactic treatment of mammalian sexual disorders.
